NCT01757015
Withdrawn
Phase 3
A 26-week Multi-center Randomized Double-blind Study to Compare Efficacy and Safety of NVA237 Versus Placebo as an add-on to Maintenance Therapy With Fixed-dose Combination Salmeterol/Fluticasone Propionate in COPD Patients With Moderate to Severe Airflow Limitation
ConditionsChronic Obstructive Pulmonary Disease
Overview
- Phase
- Phase 3
- Intervention
- NVA237
- Conditions
- Chronic Obstructive Pulmonary Disease
- Sponsor
- Novartis Pharmaceuticals
- Primary Endpoint
- Trough Forced Expiratory Volume in 1 second (FEV1)
- Status
- Withdrawn
- Last Updated
- 9 years ago
Overview
Brief Summary
This study is to evaluate if add-on treatment with inhaled NVA237 (50 µg) once daily (o.d.) via single-dose dry-powder inhaler (SDDPI) further improves lung function and health status and is well tolerated compared to placebo in symptomatic COPD patients with moderate to severe airflow limitation who are already receiving maintenance therapy with inhaled fixed-dose-combination of salmeterol/fluticasone propionate (50/500 µg) twice daily (b.i.d.) via multi-dose dry powder inhaler (MDDPI).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Current or ex-smokers who have a smoking history of at least 10 pack years (e.g., 10 pack years = 1 pack/day × 10 years, ½ pack/day × 20 years, etc.).
- •COPD (Chronic Obstructive Pulmonary Disease) patients with moderate to severe airflow limitation (Spirometry classification: GOLD 2 or 3) at Visit 2:
- •Post-bronchodilator FEV1 (Forced Expiratory Volume in one second) ≥30% and \<60% of the predicted normal, and,
- •Post-bronchodilator FEV1/forced vital capacity (FVC) \<0.70
- •Patients on maintenance treatment with fixed-dose combination of inhaled salmeterol and fluticasone propionate (50/500 µg) b.i.d. delivered via a proprietary MDDPI (multidose dry powder inhaler) device for at least 30 days prior to screening visit (Visit 1).
- •Patients in category Gold B or D with a CAT (COPD Assessment Test) total score ≥10 at screening (Visit 1) and before randomization (Visit 3).
- •Patients with a history of at least 1 moderate or severe COPD exacerbation within the previous year.
Exclusion Criteria
- •Pregnant or nursing (lactating) women
- •Women of child-bearing potential, unless they are using effective methods of contraception during the study
- •Patients with a history of long QT syndrome or whose QTc measured at run-in (Visit 2) (Fridericia method) is prolonged (\>450 ms). (These patients cannot be re-screened.)
- •Patients with evidence (upon visual inspection) of oropharyngeal candidiasis at baseline with or without treatment.
- •Patients who have not achieved an acceptable spirometry result at run-in (Visit 2) in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) criteria for acceptability and repeatability.
- •Patients who have had a COPD exacerbation that required treatment with antibiotics or oral corticosteroids or hospitalization in the 6 weeks prior to screening (Visit 1).
- •Patients who have had a respiratory tract infection within 4 weeks prior to screening (Visit 1).
- •Patients requiring long term oxygen therapy prescribed for \>12 hours per day.
- •Patients with allergic rhinitis who use an H1 antagonist or intra-nasal corticosteroids intermittently. (Treatment with a stable dose or regimen is permitted.)
- •Patients with concomitant pulmonary disease (e.g., lung fibrosis, sarcoidosis, interstitial lung disease, or pulmonary hypertension), clinically significant bronchiectasis, or history of pulmonary lobectomy, lung volume reduction surgery, or lung transplantation.
Arms & Interventions
NVA237
NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening.
Intervention: NVA237
Placebo
Placebo to NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening
Intervention: Placebo to NVA237
Outcomes
Primary Outcomes
Trough Forced Expiratory Volume in 1 second (FEV1)
Time Frame: after 12 weeks of treatment
Comparison of NVA237 treatment versus placebo treatment in the trough FEV1 after 12 weeks of treatment
Secondary Outcomes
- Total score of St George's Respiratory Questionnaire for COPD patients (SGRQ-C).(26 weeks)
- Trough Forced Expiratory Volume in 1 second (FEV1)(week 4 , week 26)
- Total score of the Transition Dyspnea Index (TDI)(Week 12 and week 26)
- Assessment of safety and tolerability(26 Weeks)
Similar Trials
Completed
Phase 3
Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)NCT01566604Novartis Pharmaceuticals460
Completed
Phase 3
Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)NCT01604278Novartis Pharmaceuticals449
Completed
Phase 2
Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)NCT00510510Novartis281
Completed
Phase 2
A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary DiseaseNCT00856193Novartis33
Withdrawn
Phase 3
Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.Pulmonary Disease, Chronic ObstructiveNCT01837927Novartis Pharmaceuticals